FindMyKOL
Clinical trialNCT00565773CompletedPhase 2Interventional

Belatacept Post Depletional Repopulation to Facilitate Tolerance

NCT00565773 is a phase 2 interventional trial sponsored by Allan D Kirk, MD, PhD. As of 21 Nov 2026, it is completed. It studies Alemtuzumab, Belatacept and Sirolimus in Organ Transplantation. The registry lists an enrollment of 40 participants at 2 sites in 1 country. The registry lists a start date of 31 Dec 2007 and a primary completion date of 1 Jul 2017.

SponsorAllan D Kirk, MD, PhDEnrollment40Organ Transplantation
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00565773
FieldValue
Registry IDNCT00565773
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorAllan D Kirk, MD, PhD
Enrollment40
Registered sites2
Countries1
ConditionsOrgan Transplantation
DrugsAlemtuzumab, Belatacept and Sirolimus
Start31 Dec 2007
Primary completion1 Jul 2017
Study completion1 Jul 2017
Last update posted11 Feb 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney. Rejection typically most often develops in the first few months after a transplant. This single center study will seek to determine if a new combination of anti-rejection medications, including the recently FDA approved drug called Belatacept, is better than the current standard anti-rejection drug regimen at preventing rejection. Also to be determined will be whether the new combination of drugs will allow participants to wean off their oral anti-rejection medications over time. This study will test the safety and effectiveness of a new investigational drug combination using alemtuzumab, belatacept, and sirolimus when given with or without donor bone marrow. This combination of medicines has not been tested before in humans. Alemtuzumab (Campath) is approved for use in some types of white blood cell cancers, but is considered investigational in transplant patients. Belatacept is now FDA approved and is being studied in transplant patients. Sirolimus (Rapamune) is approved for use in transplant patients, but its use with belatacept and alemtuzumab is investigational. In the initial 20 subjects enrolled in the study, half tested whether an infusion of bone marrow from the kidney donor would improve the effect of these drugs. This bone marrow infusion was also considered investigational. Enrollment of 20 additional subjects began in January, 2013. The donor bone marrow infusion has been eliminated. Enrollment was open to primary living and deceased donor kidney recipients. Enrollment was closed as of 8/12/2014.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States2 sites
  • Emory University Hospital

    Atlanta

  • the Emory Clinic

    Atlanta

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 2 sitesGA2HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00565773

Each answer restates registry values shown on this page.

What is NCT00565773?

NCT00565773 is a phase 2 interventional trial sponsored by Allan D Kirk, MD, PhD. It studies Alemtuzumab, Belatacept and Sirolimus in Organ Transplantation.

Who leads NCT00565773?

The registry names Antonio Guasch, MD (principal investigator, Emory University) as the overall official.

Where does NCT00565773 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00565773 study?

The registered drug and biological interventions are Alemtuzumab, Belatacept and Sirolimus.

When did NCT00565773 end?

The registry lists a primary completion date of 1 Jul 2017 and a study completion date of 1 Jul 2017. The sponsor last updated the record on 11 Feb 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.